<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99044</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The relationship between comorbidity, anemia and response to erythropoiesis-stimulating agents in chronic hemodialysis</dc:title>
<dc:description xml:lang="en">Introduction: Patients treated with haemodialysis have a highprevalence of co-morbidity that induces a elevate mortality risk. On the other hand, these patients have anaemia whose treatment is based in eritropoyesis stimulating agents. To date there are not enough studies to determine if co-morbidity alters erythropoietin response and the relationship between co-morbidity, response to treatment of anaemia and resistance to erythropoiesis-stimulating agents. Objectives: We have the following Objectives: i) to study the prevalence of associated diseases in patients treated with haemodialysis in our Hospital Unit and to evaluate the co-morbidity Charlson Index; ii) to know the degree of anaemia control, dose and response to erythropoiesis-stimulating agents, and iii) to determine the relationship with comorbidity and anaemia treatment. Patients and methods: We designed a retrospective study in stable haemodialysis treated patients. We calculated the Charlson co-morbidity index adjusted to age and we analysed levels of haemoglobin in the 6months before study, dose of erythropoiesis-stimulating agents and its resistance index defined as doses of erythropoiesis-stimulating agents/weight (kg)/week/haemoglobin (g/dL). The different variables included in Charlson index were considered as independent variables and the index to repose to erythropoiesisstimulating agents as a dependent variable, using bivariant and multivariate statistical analysis. Results: We included 58 patients(31 males and 27 females), median age of 69.5 years (range 24-88), mean haemodialysis 83,7 months. Mean Charlson index was 7.4 ± 2.8 (range 2-13). Comorbidity-age Charlson index was 2 in 3.4% of patients; 10.3% had 3 or 4 points; 43.2% between 5 and 7 and 43.1% 8 or more. Mean haemoglobin levels was 11.7±1.2 g/dL. Mean erythropoiesis-stimulating agents dose was 163.7 ± 114.5 IU/kg/week and resistance index 14.1 ± 9.7. Most of patients (57%) had a IRE value higher than 10. Forteen patients (24%) had haemoglobin less than 11 g/dL, and 3 of them (5.1%) received erythropoiesis-stimulating agents more than 300 IU/kg/week. Nine subjects (15.5%) was treated with high dose of erythropoiesis-stimulating agents (&gt; 300 IU/kg/week): 3 of them had Hb &amp;#8805; 11 g/dL and 6 had Hb &lt; 11 g/dL. We did not found that the intensity of Charlson index is related with the degree of anaemia control or response to erythropoiesis-stimulating agents. Conclusions: Althought in our study the comorbidity index is high and the response to erythropoiesis-stimulating agents is inadequate, there is not relationship between these conditions  (AU)</dc:description>
<dc:creator>Caparrós, G</dc:creator>
<dc:creator>Vozmediano, C</dc:creator>
<dc:creator>Alcaide, MP</dc:creator>
<dc:creator>Arambarri, M</dc:creator>
<dc:creator>Anaya, S</dc:creator>
<dc:creator>Nieto, J</dc:creator>
<dc:creator>Sánchez de la Nieta, MD</dc:creator>
<dc:creator>Carreño, A</dc:creator>
<dc:creator>Ferreras, I</dc:creator>
<dc:creator>Rivera, F</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Los pacientes en hemodiálisis presentan un elevado número de patologías asociadas. Por otro lado, la mayoría reciben derivados eritropoyéticos como tratamiento de la anemia. No hay estudios que indiquen si el grado de comorbilidad influye en la respuesta a los derivados eritropoyéticos. Objetivos: Estudiar la comorbilidad de los pacientes de una unidad de hemodiálisis hospitalaria, cuantificarla mediante el índice de comorbilidad de Charlson, conocer el control de anemia, la respuesta a derivados eritropoyéticos y, finalmente, evaluar la relación entre comorbilidad y control y tratamiento de la anemia. Pacientes y métodos: Realizamos un estudio retrospectivo. Incluimos 58 pacientes en hemodiálisis del Hospital General de Ciudad Real. Recogimos datos de la historia clínica para calcular el índice de comorbilidad de Charlson. Analizamos las cifras de hemoglobina y las dosis de derivados eritropoyéticos en los seis meses previos y calculamos el índice de resistencia a derivados eritropoyéticos. Las distintas entidades incluidas en el índice de comorbilidad y el propio índice de comorbilidad se consideraron variables independientes y el índice de resistencia a derivados eritropoyéticos como variable dependiente, mediante análisis uni y multivariante. Resultados: Edad media 69,5años; 53,4% varones; tiempo medio en hemdiálisis 83,7meses. El índice de Charlson medio fue 5,2 ± 2,4 (2-11) y el ajustado a la edad 7,4 ± 2,8 (2-13). La hemoglobina media fue 11,7 ± 1,2 g/dL. El 24,1% presentaban hemoglobina inferior a 11 g/dL. La media del índice de resistencia a derivados eritropoyéticos fue 14,1 ± 9,7. No observamos que los valores del índice de Charlson se relacionaran con el grado de anemia ni con la resistencia a derivados eritropoyéticos. Conclusiones: En nuestra muestra existe una elevada comorbilidad asociada y un porcentaje importante de pacientes con anemia no controlada. No hemos encontrado relación entre la comorbilidad y el control de la anemia ni el grado de respuesta a derivados eritropoyéticos (AU)</dc:description>
<dc:source>Nefrologia;28(2): 186-192, mar.-abr. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-99044</dc:identifier>
<dc:title xml:lang="es">Relación entre comorbilidad, anemia y respuesta a derivados eritropoyéticos en pacientes incluidos en programa de hemodiálisis periódicas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d755^s22080</dc:subject>
<dc:subject>^d50497^s22012</dc:subject>
<dc:subject>^d29407^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d37776</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:type>article</dc:type>
<dc:date>200804</dc:date>
</metadata>
</record>
</ibecs-document>
